These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26310004)

  • 1. [Evaluating the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration and concomitant glaucoma].
    Erichev VP; Budzinskaya MV; Karpilova MA; Yulova AG; Smirnova TV; Andreeva IV; Shchegoleva IV; Plyukhova AA
    Vestn Oftalmol; 2015; 131(3):27-33. PubMed ID: 26310004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.
    Shin JY; Woo SJ; Ahn J; Park KH
    Korean J Ophthalmol; 2013 Dec; 27(6):425-32. PubMed ID: 24311928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
    J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.
    Saleh R; Karpe A; Zinkernagel MS; Munk MR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):817-824. PubMed ID: 28127658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration.
    Valverde-Megías A; Ruiz-Calvo A; Murciano-Cespedosa A; Hernández-Ruiz S; Martínez-de-la-Casa JM; García-Feijoo J
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1459-1466. PubMed ID: 31053943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration.
    Kim M; Kim ES; Seo KH; Yu SY; Kwak HW
    Indian J Ophthalmol; 2016 Jun; 64(6):427-33. PubMed ID: 27488150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Age-related macular degeneration and glaucoma: intraocular pressure monitoring after intravitreal injections].
    Avetisov SE; Erichev VP; Budzinskaia MV; Karpilova MA; Gurova IV; Shchegoleva IV; Chikun EA
    Vestn Oftalmol; 2012; 128(6):3-5. PubMed ID: 23367753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
    Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
    Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.